News & Perspective

Sep 05, 2002

Sep 05, 2002

Acambis reports successful phase I trial of cell-culture-grown smallpox vaccine

(CIDRAP News) Ð The smallpox vaccine being produced by Acambis plc for the US government as part of the nation's bioterrorism preparedness program worked well in a Phase I trial, Acambis officials announced this week.

The vaccine, called ACAM1000, generated a characteristic skin lesion or "take" in all those vaccinated, and there were no serious or unusual side effects, the company reported in a Sep 3 news release.